Stay updated on Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.

Latest updates to the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.8%
- Check16 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.0%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check37 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in its functionality.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.SummaryDifference1%
Stay in the know with updates to Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib+Bendamustine/Rituximab in Mantle Cell Lymphoma Clinical Trial page.